Core Insights - Aurora Cannabis Inc. is recognized as one of the 12 best marijuana stocks to buy according to analysts [1] - The company, in collaboration with Copeia, has launched an English-language version of the Physician Experience Platform (PEP), which includes over 130 anonymized case studies on medicinal cannabis treatments [1][2] - PEP aims to provide healthcare professionals with access to peer-reviewed clinical insights and is initially available in several countries including Canada, the UK, and Australia [1][2] Company Developments - The PEP platform builds on a successful German launch in 2024 and is secured by a DocCheck login for verified physicians [2] - Aurora Cannabis operates in the global medicinal and consumer cannabis markets under various brands such as MedReleaf, CanniMed, Drift, and San Rafael '71 [2] - The company intends to create an international medical cannabis case study database for physicians to upload cases in the future [2]

Industry Overview - The U.S. administration is considering reclassifying marijuana from Schedule I to Schedule III under the Controlled Substances Act, which could significantly impact the marijuana industry by allowing businesses to access standard banking and reducing their effective tax rates [2] - Currently, marijuana's Schedule I classification limits business deductions under Section 280E of the federal tax code, which could change with reclassification, potentially increasing profitability and attracting institutional investors [2] Analyst Insights - TD Cowen analyst Jaret Seiberg suggests that former President Trump may revive efforts to move cannabis to Schedule III, allowing for government regulation [3] Best Marijuana Stocks - **Aurora Cannabis Inc. (NASDAQ: ACB)**: Analysts project an upside potential of 4.55%. The company launched the Physician Experience Platform (PEP) to provide healthcare professionals with access to clinical insights on medicinal cannabis treatments [8] - **Turning Point Brands, Inc. (NYSE: TPB)**: Analysts project an upside potential of 5.47%. The company launched Stoker's Fine Cut Wintergreen in a compact can, responding to consumer demand and enhancing its moist smokeless tobacco line [9][10] - **The Scotts Miracle-Gro Company (NYSE: SMG)**: Analysts project an upside potential of 12.90%. The company made significant strides in sustainability, including reducing water usage for greenhouse irrigation by over 50% and achieving 100% recyclable packaging for its products [11][12]

Industry Overview - The cannabis sector has experienced significant volatility and downtrends, making it challenging for investors to achieve decent returns [1][2] - Despite these challenges, the cannabis industry is progressing and remains profitable, with growing markets in Europe, Canada, and parts of South America [2][3] - Recent trading indicates a potential resurgence in the cannabis sector, driven by ongoing federal reform efforts in the USA [3] Company Highlights - **Cronos Group Inc.**: Engages in the cultivation, production, distribution, and marketing of cannabis products internationally. Reported Q2 2025 earnings on August 7 [4] - **SNDL Inc.**: Focuses on the production, distribution, and sale of cannabis products for the adult-use market in Canada. Announced its 2025 Annual and Special Meeting of Shareholders at the end of July [5][7] - **Aurora Cannabis Inc.**: Involved in the production, distribution, and sale of cannabis and cannabis-derivative products globally. Recently launched an English-language version of the Physician Experience Platform in collaboration with Copeia [8][9] Financial Performance - **SNDL Inc.**: Reported net revenue of $33.5 million in Q2 2025, an increase of $5.7 million from Q2 2024. Gross profit was $14.5 million, up by $8.2 million from the previous year. However, net loss increased to $38.5 million, up by $29.7 million from Q2 2024. Adjusted EBITDA improved to $1.7 million, a $12.7 million increase from Q2 2024 [6]